XARELTO Market Size, Forecast, and Market Insight - 2032

This “XARELTO Market Size, Forecast, and Market Insight − 2032” report provides comprehensive insights about XARELTO for Peripheral Artery Disease (PAD) in the United States and Japan. A detailed picture of the XARELTO for PAD in the United States and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the XARELTO for PAD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XARELTO market forecast analysis for PAD in the US and Japan, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PAD.

Drug Summary

XARELTO is an oral anticoagulant for the treatment and prevention of blood clots. In combination with aspirin, it is indicated to reduce the risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology) in adult patients with PAD, including patients who have recently undergone a lower extremity revascularization procedure due to symptomatic PAD. XARELTO can cause bleeding, which can be serious and may lead to death, as it is a blood thinner medicine (anticoagulant) that lowers blood clotting. Thus the drug has a boxed warning from FDA.

XARELTO is the first and only therapy indicated for both coronary artery disease (CAD) and PAD, including PAD patients post-LER. In addition, it is also the only anticoagulant in 20 years to show significant benefit in patients with PAD who remain at high risk for major thrombotic events, including acute limb ischemia and amputation.

Dosage and Administration

The recommended dose of XARELTO is 2.5 mg orally twice daily with or without food, in combination with aspirin (75–100 mg) once daily. No dose adjustment was needed for renal considerations.

Mechanism of action

XARELTO is a selective inhibitor of FXa, and it does not require a cofactor (such as anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity; rivaroxaban does not directly affect platelet aggregation but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the XARELTO description, mechanism of action, dosage and administration, research and development activities in Peripheral Artery Disease (PAD).
• Elaborated details on XARELTO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the XARELTO research and development activities in PAD across the United States and Japan.
• The report also covers the patents information with expiry timeline around XARELTO.
• The report contains forecasted sales of XARELTO for PAD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for PAD.
• The report also features the SWOT analysis with analyst views for XARELTO in PAD.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XARELTO Analytical Perspective

In-depth XARELTO Market Assessment

This report provides a detailed market assessment of XARELTO for Peripheral Artery Disease (PAD) in the United States and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

XARELTO Clinical Assessment

The report provides the clinical trials information of XARELTO for PAD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Peripheral Artery Disease (PAD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XARELTO dominance.
• Other emerging products for PAD are expected to give tough market competition to XARELTO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XARELTO in PAD.
• This in-depth analysis of the forecasted sales data of XARELTO from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XARELTO in PAD.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of XARELTO?
• What is the clinical trial status of the study related to XARELTO in Peripheral Artery Disease (PAD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XARELTO development?
• What are the key designations that have been granted to XARELTO for PAD?
• What is the forecasted market scenario of XARELTO for PAD?
• What are the forecasted sales of XARELTO in the US and Japan?
• What are the other emerging products available and how are these giving competition to XARELTO for PAD?
• Which are the late-stage emerging therapies under development for the treatment of PAD?

This product will be delivered within 2 business days.